-
The chance of dying after receiving the Janssen vaccine is about 1:2,000,000. But with multiple COVID-19 vaccines available, the FDA is limiting the use of the J&J vaccine.
-
Companies that aren't bankrupt are using controversial maneuvers in U.S. bankruptcy court to block tens of thousands of suits. A woman suing Johnson & Johnson died while her case was in legal limbo.
-
Though people who are vaccinated and boosted appear to be better protected against omicron, the highly contagious variant has still led to breakthrough cases and a surge in infections worldwide.
-
Two studies that have not yet been peer reviewed indicate increased protection against the infectious omicron variant.
-
The agency implemented experts' advice because of a rare and sometimes fatal blood-clotting problem known as TTS. More than 16 million people in the U.S. have received a shot of the J&J vaccine.
-
CDC Director Rochelle Walensky also endorsed a mix-and-match approach to boosters that would be flexible for patients and health care providers.
-
The Food and Drug Administration also gave an OK to boosters that differ from the vaccine originally used to immunize people against COVID-19. A mix-and-match approach could ease the booster rollout.
-
A panel of experts voted to recommend that the Food and Drug Administration authorize a booster dose of the Johnson & Johnson COVID vaccine at least two months after the first shot.
-
Johnson & Johnson has asked the Food and Drug Administration to authorize a booster for people 18 and older six months after initial immunization, with an option to vaccinate after two months.
-
The Food and Drug Administration released briefing documents Tuesday on booster shots for the Moderna and Johnson & Johnson COVID vaccines ahead of a two-day advisory meeting that starts Thursday.
-
Johnson & Johnson shared data from its Phase 3 trial of the company's booster shot on Tuesday. The data showed a booster shot at six months provided a 12-fold increase in antibodies.
-
Payouts will be spread over the next 18 years, with much of the funding going to help communities struggling with high rates of opioid addiction and overdose deaths.